Krystal Biotech (NASDAQ:KRYS – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.
Institutional and Insider Ownership
86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Krystal Biotech and Connect Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Krystal Biotech | 0 | 2 | 10 | 2 | 3.00 |
| Connect Biopharma | 1 | 0 | 7 | 0 | 2.75 |
Profitability
This table compares Krystal Biotech and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Krystal Biotech | 54.82% | 19.34% | 17.65% |
| Connect Biopharma | N/A | -165.41% | -121.58% |
Risk and Volatility
Krystal Biotech has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500.
Earnings & Valuation
This table compares Krystal Biotech and Connect Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Krystal Biotech | $389.13 million | 24.69 | $204.83 million | $7.98 | 40.67 |
| Connect Biopharma | $60,000.00 | 991.46 | -$55.48 million | ($1.19) | -0.79 |
Krystal Biotech has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Krystal Biotech beats Connect Biopharma on 12 of the 15 factors compared between the two stocks.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
